Add the specialty areas of your choice to tailor to your professional interests.
Save & Create free account
No thanks, just apply selection
I already have an account. Login

User login

We offer our registered users tailored information, free online courses and exclusive content.

Can't find your password?
Reset it here.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Amit Bar-Or

Amit Bar-Or
Neurologist and Professor
Department of Neurology and Neurosurgery
Clinical Research Unit
Montreal Neurological Institute
Montreal, Canada

Dr. Bar-Or is a neurologist and Professor, Department of Neurology and Neurosurgery, McGill University and Associate Director of the Montreal Neurological Institute and Hospital (Translational), where he also serves as Director of the Experimental Therapeutics Program and Scientific Director of the Clinical Research Unit. His clinical focus is Multiple sclerosis and related conditions, in both adults and children, and he presently serves as President of the Canadian Network of MS Clinics (CNMSC).  Dr. Bar-Or’s Neuroimmunology lab examines mechanisms of immune regulation with particular focus on defining functionally distinct immune cell subsets and their roles in autoimmune diseases, as well as immune-glial and immune-neural interactions, and how such interactions contribute to injury and repair in the central nervous system (CNS). An overall emphasis is on translational and biomarker development work in humans, including deep immune-monitoring of well-characterized patient cohorts participating in experimental therapeutic trials. This combination allows for translation of basic lab discoveries to understanding and development of novel experimental therapies for patients with autoimmune and neurological diseases.  

Dr. Bar-Or has received multiple accolades for his research, is a lecturer in great demand. He coordinates several multi-center national and international translational research initiatives and serves on the scientific boards of the Guthy-Jackson Greater-Good Foundation for NMO research and the Accelerated Cure Project, (ACP), and on the Boards and/or Scientific Advisories of the American Committee for Treatment in MS (ACTRIMS); The International Society for Neuroimmunology (ISNI) and the German National Kompetenz Network in Neuroimmunology. He is on the Steering Committee of the Immune Tolerance Network, serves as Chair of CME and member of the Education Committee of the Federation of Clinical Immunology Societies (FOCIS), and as member of several editorial boards including Neurology, and Clinical and Experimental Neuroimmunology.